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Summary The value of DNA ploidy as a prognostic indicator is well established in many cancers, but recent
studies in childhood rhabdomyosarcoma (RMS) have been contradictory. In a retrospective study of 128 cases
of soft-tissue sarcoma (STS) diagnosed since 1980, the prognostic value of clinical, histological and flow
cytometric parameters was compared, using univariate and multivariate methods. Eighty-one RMSs, 18
extraosseous Ewing's (EOE)/peripheral neuroectodermal tumours (PNETs) and 29 other non-RMS STSs were
histologically and clinically reviewed. Five year actuarial survival was 63.4% for all STSs and 69.4% for
RMSs. Paraffin-embedded tissue blocks were available for flow cytometry in 90 cases. Of the RMSs, 65.5%
were aneuploid [DNA index (DI) > 1.1] compared with 23% of the EOE/PNETs and 31% of non-RMS STSs.
Median S-phase was also significantly higher in RMSs (17.0%) than in other STSs (10.8%) (P = 0.0023).
Univariate analysis in RMSs showed that stage, ploidy status, S-phase, site and tumour size all had a
significant impact on survival. In multivariate analysis of 59 cases of RMS, one clinical and two flow
cytometric parameters were independently associated with poor prognosis. These were stage (IV), non-
hyperdiploidy (DI <1.10 and > 1.8) and a high rate of proliferative activity (S-phase > 14.0%). These results
confirm that ploidy and S-phase are important new prognostic indicators in rhabdomyosarcoma.
The successful cure of about 60% of children with STS has
focused attention on the identification of those who fail
therapy and on the late effects of successful treatment. In
RMS, which accounts for approximately 60% of all STSs,
certain clinical and pathological characteristics have been
related to prognosis with varying consistency, of which the
most important are tumour site, stage and histological sub-
type (Rodary et al., 1991). More accurate identification at or
soon after diagnosis of individuals who are at high risk of
treatment failure would allow therapy to be intensified in a
selected group of patients. Conversely, the identification of
patients with a very good prognosis may allow the intensity
of therapy to be reduced, decreasing the risk of long-term
toxicity. It is likely that exploration of their biological char-
acteristics will emphasise the heterogeneous nature of
tumours which, by conventional criteria, may seem to have a
similar chance of successful treatment. The evaluation of
ploidy, chromosomal abnormalities, oncogene amplification
and multidrug resistance phenotype are examples of such an
approach (Anonymous, 1989).
Measurement ofcellular DNA content has become increas-
ingly common. The relationship between abnormalities in
DNA content or proliferative characteristics and prognosis
has been explored for a variety of malignancies (Merkel et
al., 1987), particularly as methods for applying these tech-
niques to formalin-embedded tissue have been established
(Hedley et al., 1983). Nevertheless, there are very few reports
of this in childhood soft-tissue sarcoma, and the results are
not consistent. While some authors suggest a better response
to chemotherapy in aneuploid (Boyle et al., 1988; Molenaar
et al., 1988) or hyperdiploid RMSs (Shapiro et al., 1991)
compared with their diploid counterparts, others could not
confirm an association of ploidy with survival in this tumour
category (Kowal-Vern et al., 1990; Leuschner et al., 1991;
Dias et al., 1992).
In this report we investigate the value of DNA measure-
ment and proliferative activity in childhood STSs in a retro-
spective study using formalin-fixed and paraffin-embedded
tumour specimens.
Patients and methods
All patients with STS under the age of 16 years treated at
The Children's Hospital Birmingham (UK) between 1980 and
1992 were reviewed and restaged according to the SIOP
TNM staging system (Rodary et al., 1989). Additionally the
following clinical parameters were investigated: tumour site,
size (less or more than 5 cm), post-surgical staging (macro-
scopic and microscopic complete or incomplete excision),
radiotherapy, age and sex. A total of 121 patients with STS
(74 RMS, 18 extraosseous Ewing's sarcoma (EOE) or
peripheral neuroectodermal tumour (PNET) and 29 other
non-rhabdomyosarcomatous soft-tissue sarcomas, non-RMS
STSs) were identified after confirmation of diagnosis by a
panel of at least three paediatric histopathologists. Prior to
1989, children with RMS were treated according to IRS
protocols (IRS II and III) (Ragab et al., 1992; Maurer et al.,
1993), and since then according to the SIOP MMT-89
strategy (Stevens et al., 1991).
In addition we investigated a selected group of seven child-
ren with alveolar RMS treated at the Royal Marsden Hos-
pital, Sutton, Surrey, UK, in order to increase the numbers
of patients available for analysis in this subgroup, which was
underrepresented in the above series.
Cytometric investigations included measurement of ploidy
(DNA index) and proliferation activity (S-phase). Represen-
tative formalin-fixed and paraffin-embedded tissue blocks
were available for flow cytometry in 90 (70%) cases. Fifty
micron sections were prepared by a modified version of that
described by Hedley et al. (1983). Analysis of 5,000-10,000
cells (after the exclusion of low fluorescent particles and
debris) was performed using a Coulter 'EPICS Profile II'
flowcytometer with an argon laser light source. Samples
from normal tonsil served as external controls for monitoring
consistency of technique between batches. Normal cells
within the tissue sample acted as internal controls. For
analysis Coulter Cytology DNA software was used. This
program compensates for doublets and overlapping nuclei.
The coefficient of variation ranged from 2.29% to 13.87%
(median 4.97%). If the coefficient of variation of the GO/GI
peak was above 8%, the DNA histogram was accepted only
if there was a second peak distinguishable in the sample. Two
cell populations could be distinguished when there was a
difference of at least 6% in their DNA content. The propor-
tion of cells in the S-, G2 and M-phases of the cell cycle was
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used as an index of proliferative activity of the tumour. The
S-phase fraction was calculated with the model of multiple
broadened rectangles or dual cycling populations (Baish et
al., 1982; Scott et al., 1992).
Flow cytometric analysis disclosed the presence of four
distinct categories of cellular DNA content (Figure 1). The
presence of a single GO/GI peak indicated a diploid tumour.
A DNA index (DI) of 1.0 referred to a diploid cell line,
between 1.0 and 1.09 was called 'near-diploid' and the term
'hyperdiploid' was used to characterise cell populations with
a DI between 1.10 and 1.80. 'Tetraploid' denoted a cell
population with a DNA index between 1.81 and 2.20. A fifth
category, 'hypertetraploid', has been used in the literature to
describe tumours with a DNA index above 2.20, but since
only two hypertetraploid cases were found in this series, they
have been included in the tetraploid category. For the pur-
pose of analyses the diploid and near-diploid categories were
combined.
The prognostic value of clinical parameters and flow
cytometric parameters (DI and S-phase) was investigated
using univariate methods, namely the log-rank test, and by
multivariate methods using a stepwise Cox's proportional
hazards model. Differences in median S-phase were investi-
gated with the Kruskal-Wallis test, and the chi-square test
was used to assess differences in ploidy.
Results
Five year actuarial survival in this series was 63.4% for all
STSs and 69.4% for RMSs. Distributions of tumour his-
tology, ploidy pattern and S-phase are shown in Table I.
There were significant differences in DNA content and
proliferative activity (S-phase) between the three major histo-
logical categories of STS. Sixty-six per cent (40/61) of RMSs
were aneuploid (DNA index >1.10) compared with 23%
(3/13) of the EOE/PNET and 31% (5/16) of the non-RMS
STSs (P = 0.003). Eighteen per cent (2/11) of alveolar RMSs
were tetraploid compared with 12% (6/50) of embryonal
RMSs. The frequency distribution of DNA indices in the
different subtypes is shown in Figure 2. Whereas the DNA
content of the embryonal RMSs was distributed over the
whole range of hyperdiploidy and tetraploidy, only 1 (a
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malignant fibrous histiocytoma) out of 29 non-RMS STSs had
a DI above 1.30. S-phase ranged from 3.3% to 34%. Median
S-phase in RMSs was 17.0% compared with 9.7% in EOE/
PNET and 10.1% in non-RMS STSs (P = 0.0023). Median
S-phase differed significantly in RMSs between the three
categories diploid/near-diploid, hyperdiploid and tetra-
ploid, with values of 19.6% (range 6-30%), 13.3%
(5.6-26.2%) and 19.5% (9.8-34%) respectively (P<0.05).
Analysis of the effect on survival of clinical and cytometric
parameters was undertaken for 81 RMS cases (Table II).
Three clinical parameters (stage, tumour size and site), ploidy
and S-phase were found to have a significant impact on
survival. Overall survival by ploidy and S-phase are shown in
a Kaplan-Meier analysis in Figures 3 and 4.
Five year survival rate in hyperdiploid RMS (DI
1.10-1.79) was 88.3% compared with 28.6% in tetraploid
(DI > 1.80), 44.4% in near-diploid (DI 1.0-1.09) and 58.3%
in diploid tumours (P=0.0003). Since there was no
significant difference between diploid and near-diploid
tumours, these two categories were combined (5 year survival
54.6%). Ninety-five per cent ofchildren with an RMS and an
S-phase below 14% were alive after 5 years compared with
50% with an S-phase above 14%. In the univariate analysis
not only did tetraploid RMS have a significantly decreased
survival compared with the hyperdiploid tumours, but also
the outcome of the diploid/near-diploid category was
significantly worse (P = 0.0054).
Multivariate analysis (Table III) could be performed on 59
cases with complete data and revealed that stage IV disease,
tetraploidy, diploidy/near diploidy and S-phase (> 14%)
were independently associated with significantly poorer sur-
vival. The threshold at 14% was selected by the stepwise
analysis as the most discriminating variable.
When the analysis was repeated using only non-metastatic
patients (stage I-III, 48 cases), hyperdiploidy was even more
significant (relative hazard 12.24) and S-phase remained an
independent prognostic indicator.
Discussion
Ploidy has been evaluated and correlated with the outcome
of treatment in several childhood malignancies. It is well
Near-diploid (1.0-1.09)
DI = 1.08
Tetra-hypertetraploid (>1.80)
DA = 2.30
DNA content
Figure 1 Ploidy pattem.
Di = 1.15
a L .
0
I
I r- ,1108 F.K. NIGGLI et al.
Table I DNA ploidy in soft-tissue sarcomas
Ploidy pattern/S-phase
Tetra-I
Source of tissue Total Diploid Near-diploid Hyperdiploid hypertetraploid Median S-phase
Rhabdomyosarcoma 61 11 (18%) 10 (15%) 32 (49%) 8 (17%) 17.0%
Embryonal 50 8 (16%) 5 (10%) 31 (62%) 6 (12%) 16.2%*
Alveolar 11 3 (27%) 5 (45%) 1 (9%) 2 (18%) 22% *
PNET/EOE 13 7 (57%) 3 (21%) 3 (21%) 0 9.7%
Other sarcomas 16 8 (50%) 3 (19%) 5 (31%) 0 10.1%
*Median S-phase significantly different (P = 0.021) between embryonal and alveolar RMSs.
Table II Univariate analysis of survival in 81 RMSs
Factor No. Five year survival (%) P (log-rank test)
Stage
I 15 90.9 0.0001
II 43 73.6
III 10 85.7
IV 13 10.8
Ploidy
Diploid/near-diploid 21 54.6 0.0003
Hyperdiploid 32 88.3
Tetraploid 8 28.6
S-phase
,14% 35 50.1 0.001
< 14% 24 95.7
Site
Limbs 10 28.6 0.0008
Others 71 74.8
Tumour size
<5cm 29 83.8 0.0218
>5cm 52 60.3
Age, sex, histology, surgical clearance (microscopically complete) and
radiotherapy were not significant.
Table III Multivariate analysis in 59 RMSs (stepwise Cox's proportional hazard)
Poor prognosis Adjusted 95% confidence
Variable Factors feature relative hazard interval
Stage Stage IV vs others Stage IV 9.62 2.85-32.57
Ploidy Hyperdiploid vs Tetraploidy or 6.91 1.70-27.24
others diploidy/near diploidy
S-phase >14% vs <14% >14% 8.53 1.09-66.85
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recognised that in subgroups of ALL (Look et al., 1985) and
neuroblastoma (Look et al., 1984; Huddart et al., 1992),
hyperdiploid tumour stem lines seem to favour prognosis
compared with their diploid or tetraploid counterparts,
whereas this prognostic feature seems to be reversed in
Wilms' tumour and most adult tumours (Douglass et al.,
1986; Schmidt et al., 1986; Merkel et al., 1987; Barrantes et
al., 1993). Data from other tumours such as medulloblas-
toma and hepatoblastoma are conflicting (Yasue et al., 1989;
Hata et al., 1991; Zerbini et al., 1993). There are only a few
reports on the prognostic implication of DNA content in
childhood STS and the results are not consistent (Boyle et
al., 1988; Molenaar et al., 1988; Kowal-Vern et al., 1990;
Leuschner et al., 1991; Shapiro et al., 1991; Dias et al.,
1992).
The results in this study, so far the largest series evaluating
this tumour group, confirm that ploidy has a significant and
independent impact on outcome in rhabdomyosarcoma.
Although stage IV disease is the most powerful predictor of
outcome, tetraploidy/hypertetraploidy is strongly associated
with an unfavourable prognosis, whereas hyperdiploidy (DI
1.10-1.80) is usually associated with a better outcome. The
prognostic significance of the ploidy pattern was even more
apparent in non-peripheral metastatic cases. In the univariate
analysis diploid/near-diploid RMSs were associated with a
significantly decreased survival compared with the hyperdip-
loid tumours. These results are similar to those of a study in
St. Jude Children's Hospital (Shapiro et al., 1991) and of the
Intergroup Rhabdomyosarcoma Study (Pappo et al., 1993),
which found that hyperdiploidy also predicted a significantly
favourable prognosis compared with diploidy/near diploidy.
Similarly, tetraploidy was more often found in the alveolar
subtype. We looked at four additional alveolar RMSs that
were not included in this study because of age > 16 years
and found that three of them showed also tetraploidy, which
increases the number with tetraploidy within the alveolar
subtype to 33% compared with 12% in the embryonal
RMSs. The discrepancies between these findings and those of
some other studies (Leuschner et al., 1991; Dias et al., 1992),
in which no correlation between DNA ploidy and overall
survival could be found, may be explained by several factors:
sample size, pathological classification, age distribution, flow
cytometric analysis and precise ploidy definition.
In many studies, the definition of DNA ploidy does not
extend beyond 'DNA diploid' and 'DNA aneuploid', and this
pooling may mask the prognostic effect ofdifferent aneuploid
types. This study suggests that there may be three distinct
biological subtypes of RMS with different prognoses, namely
diploid/near-diploid (DI = 1.0-1.09), hyperdiploid
(DI = 1.10-1.80) and tetraploid/hypertetraploid (DI > 1.80).
In neuroblastoma it has been suggested that evolution of the
tetraploid karyotype differs from the hyperdiploid, the
former being caused by an endoreduplication from a primary
diploid or near-diploid cell line (Kaneko et al., 1987). A
similar mechanism may be involved in RMS, as is suggested
by our unpublished observations.
Flow cytometric measurement of formalin-fixed and
paraffin-embedded tissue does, however, have its limitations
and pitfalls. The intensity of the fluorochrome staining is
dependent on the use of enzymes to break down covalent
linkages between DNA and nuclear proteins caused by
fixation (Hedley et al., 1983), and the completeness of the
digestive process in each sample may be difficult to gauge.
Hence, the absolute fluorescence of the diploid populations
can vary significantly from block to block, which precludes
the use of external standards. Furthermore, hypodiploid cell
populations cannot be distinguished in paraffin sections, but
are assumed to be very rare. Nevertheless, several groups
which have compared flow cytometric profiles from fresh and
paraffin-embedded tissue (Hedley et al., 1983; Frierson, 1988;
Kallioniemi, 1988) have found a good correlation for the
DNA index. Although a minor loss of quality in archival
samples cannot be denied, and the techniques for preparing
the sample may have to be tailored for different tissue
groups, paraffin-embedded tissues are a convenient and
reasonably accurate subject for DNA ploidy.
Of more concern is the variation in DNA ploidy that may
occur in different samples of the same tumour. Intra-tumour
variation in DNA ploidy is reported in the literature in up to
25% of some tumour types (Kallioniemi, 1988), and recently
heterogeneity of DNA content was also reported in some
RMSs (Dominici et al., 1993). Multiple sampling for DI
measurement is therefore recommended.
In several studies of adult malignancies, proliferative
activity (S-phase) has been shown to be more powerful in
predicting outcome than DNA index (Herman, 1992). How-
ever, major problems in estimating the S-phase are the over-
lap with normal host cells and the fact that the accuracy of
the estimates is considerably reduced by large amounts ofcell
debris, especially in paraffin-embedded material. Com-
parisons of S-phase between different studies must be under-
taken with caution since there are different models available
for analysing the proliferative activity, and the measurement
is also dependent on the computer software used. Never-
theless, in our population, we were able to demonstrate that
S-phase had a significant impact on survival: only 1/24 child-
ren with RMS and an S-phase <14% died in this cohort of
patients. If problems of accurately measuring the cell pro-
liferative activity can be overcome, S-phase may become a
useful prognostic factor with clinical significance.
The number of cases of non-rhabdomyosarcomatous soft-
tissue sarcoma in this study was too small to allow firm
conclusions to be made. Nevertheless Ewing's/PNET and
other non-RMS STSs appear to have a different ploidy pat-
tern and a significantly lower DNA index and proliferative
activity than RMS. According to our results and a recent
study of 19 patients with PNET (Swanson et al., 1992) there
is insufficient evidence that ploidy pattern may predict out-
come in these rarer diagnoses.
We conclude that DNA content and S-phase in childhood
STS have a significant prognostic impact. The biological
behaviour of RMS can be divided at least into three different
categories according to their DNA content. Hyperdiploid
RMSs are associated with a more favourable prognosis than
diploid/near-diploid or tetraploid/hypertetraploid tumours.
Larger studies must be carried out to demonstrate this effect
when children have received the same treatment protocol
before DNA content and S-phase can be applied to the
calculation of risk factors at diagnosis and used as an addi-
tional means of stratifying the treatment required.
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